Clinical studies have shown that KIFC1 is associated with docetaxel resistance in PRAD and BRCA [18,19], with cisplatin resistance in BLCA [51], and with temozolomide resistance in GBM [52]. This evidence concerns the gene KIFC1 and bladder transitional cell carcinoma.